BI/Lilly Bring Third Entrant To SGLT2 Market With Jardiance Approval
This article was originally published in The Pink Sheet Daily
The type 2 diabetes space gets more crowded as FDA hands out another approval for an SGLT-2 inhibitor after an earlier rejection in March due to manufacturing issues.
You may also be interested in...
Some analysts expect it could take six months to resolve problems at partner Boehringer Ingelheim’s German manufacturing site, where the SGLT-2 inhibitor is made. Lilly says the European filing is not affected.
Two companies in the biopharma space began trading publicly this week, one to pay off debt, the other to fund an early-stage pipeline.
The biotech is shifting gears after clinical hold on its lead drug was unlikely to be lifted, but the early-stage candidate that it's placing its hopes on is raising red flags for analysts and investors.